Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
BACKGROUND
There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin.


METHODS
In this double-blind clinical trial, 47 patients with computed tomography (CT)-confirmed acute submassive PE treated with 1 mg/kg body weight of enoxaparin twice daily were randomized to groups receiving a 12-hour intravenous infusion of 6, 12, 18, or 24 μg/kg/hour of DAA or a placebo. Blood samples were drawn before starting DAA infusion, after 4, 8 and 12 hours (at the end of the infusion period), and on treatment days 2, 3, 4, 5 and 6.


RESULTS
Initial endogenous plasma activated protein C (APC) levels were 0.36 ± 0.48 ng/ml (<0.10 to 1.72 ng/ml) and remained in the same range in the placebo group. APC levels in patients treated with DAA were 13.67 ± 3.57 ng/ml, 32.71 ± 8.76 ng/ml, 36.13 ± 7.60 ng/ml, and 51.79 ± 15.84 ng/ml in patients treated with 6, 12, 18, and 24 μg/kg/hour DAA, respectively. In patients with a D-dimer level >4 mg/L indicating a high level of acute fibrin formation and dissolution, DAA infusion resulted in a more rapid drop in soluble fibrin, D-dimer, and fibrinogen/fibrin degradation products (FDP) levels, compared to enoxaparin alone. There was a parallel decline of soluble fibrin, D-dimer, FDP, and plasmin-plasmin inhibitor complex (PPIC) in response to treatment with enoxaparin ± DAA, with no evidence of a systemic profibrinolytic effect of the treatment.


CONCLUSIONS
In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation.


BACKGROUND
ClinicalTrials.gov: NCT00191724.
I Department of Medicine, University Medical Center Mannheim, Theodor Kutzer Ufer, Mannheim D-68167, Germany. carl-erik.dempfle@umm.de
Carl-Erik H
CE
Dempfle
Elif
E
Elmas
Andreas
A
Link
Nenad
N
Suvajac
Volker
V
Liebe
Jonathan
J
Janes
Martin
M
Borggrefe
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000378:metabolism* / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated
J Thromb Haemost. 2007 Jul;5 Suppl 1:73-80
17635713
Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2445-53
16960106
N Engl J Med. 2001 Mar 8;344(10):699-709
11236773
Thromb Haemost. 1990 Aug 13;64(1):61-8
2148848
Blood. 2007 Apr 15;109(8):3161-72
17110453
J Clin Invest. 1993 Oct;92(4):2003-12
8408654
Thromb Haemost. 1998 Apr;79(4):796-801
9569195
J Thromb Haemost. 2004 Nov;2(11):1924-33
15550023
Blood. 1992 May 1;79(9):2340-8
1571547
Blood. 2003 Sep 15;102(6):2093-8
12750166
Blood Coagul Fibrinolysis. 1993 Feb;4(1):133-7
8457641
Drugs. 2002;62(4):617-30; discussion 631-2
11893230
Crit Care Med. 2001 Jul;29(7 Suppl):S69-74
11445737
Shock. 2004 Mar;21(3):222-9
14770034
Biochim Biophys Acta. 1982 Jun 24;704(3):461-9
6214279
Intensive Care Med. 2001 Sep;27(9):1481-6
11685341
Thromb Haemost. 2003 Oct;90(4):642-53
14515185
J Infect Dis. 2002 Nov 1;186(9):1270-6
12402196
Thromb Haemost. 1988 Oct 31;60(2):328-33
2975409
J Biol Chem. 1986 Mar 15;261(8):3876-82
3005304
Circulation. 1999 Dec 21-28;100(25):2485-90
10604885
Thromb Res. 2007;121(3):377-85
17561232
J Clin Invest. 1997 Jun 1;99(11):2655-63
9169495
N Engl J Med. 1986 Oct 9;315(15):925-9
3531851
J Clin Invest. 1987 Mar;79(3):918-25
3102560